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ABSTRACT        Word count: 290 
Introduction 
Regional citrate anticoagulation (RCA) is the recommended anticoagulation modality for continuous 
renal replacement therapy (CRRT). RCA was associated with a low rate of complications in 
randomized controlled trials. However, little is known about the type and rate of complications in real 
life. We sought to describe complications associated with RCA in comparison with those associated 
with heparin anticoagulation. 
 Methods 
In our institution, RCA has been the default anticoagulation modality for CRRT in all patients without 
contra-indications since 2013. We have retrospectively reviewed all consecutive patients who 
received CRRT between January and December 2016 in our institution. For each CRRT session, we 
have assessed circuit duration, administered dose as well as therapy associated complications. Those 
parameters were compared according to whether the circuit was run in continuous veno-venous 
hemodialysis (CVVHD) mode with RCA or continuous veno-venous hemofiltration (CVVH) mode with 
heparin anticoagulation.  
Results 
We analyzed 691 CRRT sessions in 121 patients. Of those 400 (57.9%) were performed in CVVHD-
RCA mode and 291 (42.1%) in CVVH-Heparin Mode. Compared with CVVH-Heparin mode, CVVHD-
RCA mode was associated with a longer circuit lifespan (median duration 54.9 (IQR 44.6) vs 15.3 
hours (IQR 22.4), p<0.0001).). It was associated with a higher rate of metabolic acidosis (77 (20.2%) 
vs 18 (7.2%) (p<0.0001), alkalosis 186 (48.7%) vs 43 (17.1%), (p=0.0001) and hypocalcemia (96 
(25.07%) vs 26 events (10.79%), (p<0.0001). However, the majority of these alterations were of 
benign or moderate severity. Only one possible citrate intoxication was observed.  
Conclusions 
CVVHD-RCA was associated with a much longer circuit life but an increased rate of minor metabolic 
complications, in particular acid-base derangements.  Some of these complications might have been 
prevented by therapy adaptation. Medical and nursing staff education is of major importance in the 
implementation of a RCA protocol.    
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Introduction 
Regional Citrate Anticoagulation (RCA) is the recommended anticoagulation strategy for continuous 
renal replacement therapy (CRRT) in patients without contra-indications (1). The safety of RCA 
protocols has largely been addressed in many clinical conditions in several randomized controlled 
trials (2–4). Together, these studies have demonstrated RCA superiority over systemic heparin 
anticoagulation in terms of filter lifespan, bleeding complications without increasing the rate of 
metabolic alkalosis (5). Large, observational studies from centers with extensive experience with RCA 
(6) confirm these results and report a very low rate of metabolic complications and citrate 
intoxications in unselected patients undergoing CRRT. RCA might even be safe in patients with severe 
liver failure (7). 
Despite these compelling evidence and the seemingly obvious benefit of the modality, its acceptance 
and utilization remain relatively low throughout the world. Indeed, in a sub-analysis of the 
international observational Do-RE-MI-FA study (8), RCA was utilized in less than 20% of circuits 
while no anticoagulation at all was still frequently prescribed. This seems like a minor increase 
compared with the BEST KIDNEY cohort in which RCA was utilized in less than 10% of circuits (9). 
Another (yet unpublished) study from France suggested that, in units with low experience with RCA, 
filter lifespan was not superior to heparin while the rate of complication was higher. For these 
reasons, many intensivists throughout the world seem to remain reluctant to introduce RCA in their 
units as it is seen as complicated, requiring intensive training and might lead to complex metabolic 
complications. Real life data, coming from a center with intermediate experience with RCA and 
outside the context of a randomized trial are therefore needed.  
We therefore decided to retrospectively review data from all CRRT sessions performed in our center 
during the calendar year 2016, 3 years following the introduction of RCA as a default anticoagulation 
regimen for CRRT. We sought to evaluate the type and rate of complications associated with RCA 
compared with systemic heparin anticoagulation during CRRT.  
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Methods 
Ethics 
The study protocol was approved by the Ethics Committee Vaud (CER-VD 2017-00008). The need for 
specific individual informed patient consent was waived due to the observational nature of the study. 
However, patients who declined our institution general consent for data reutilization were excluded 
from the study.  
Study design 
This is a monocentric retrospective observational study conducted in the adult intensive care unit 
(ICU) of the Centre Hospitalier Universitaire Vaudois (CHUV), a tertiary, teaching hospital located in 
Lausanne, Switzerland. The ICU contains 35 beds and records approximately 2000 admissions per 
year. All consecutive patients admitted to our ICU between January and December 2016 and who 
received CRRT were included in the study. As mentioned, patients who declined consent for data 
reutilization were excluded.   
CRRT initiation 
Our institutional protocol does not specify strict recommendations for CRRT initiation. All therapies 
were evaluated on a case-by-case basis by treating physician.  
CRRT delivery 
All therapies were delivered using Multifiltrate Pro® CRRT generators (Fresenius Medical Care, Bad 
Homburg, Germany). Therapies were set in a standardized way according to our unit protocol. 
According to this protocol, RCA represented the default anticoagulation method for CRRT. In patients 
with contra-indications (PT<40% in the absence of anti-vitamin K therapy (as a marker of severe liver 
failure), serum lactate level > 4mmol/l and need for >25 µg/min of norepinephrine (as markers of 
circulatory shock), systemic anti-coagulation with heparin was considered. As per the manufacturer's 
instruction, circuits were electively replaced after 72 hours of running time. 
CVVHD-RCA 
CRRT with RCA was delivered in continuous-veno-venous-hemodialysis (CVVHD) mode with 
standard solutions (CiCa® dialysate and 4% (136 mmol/l) trisodium citrate solution) following an 
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adapted Fresenius® protocol(10). Dialysate flow rate was adapted according to patients' dry weight 
aiming for a dose slightly above 25 ml/kg/h. Citrate solution flow was started at 4 mmol per liter of 
blood and titrated according to post-filter ionized calcium measurements. Calcium reinfusion solution 
consisted in 100 mmol/l CaCl2 solution infused at a rate of 1.7 mmol/l effluent and titrated according 
to systemic ionized calcium measurements. Total calcium was regularly monitored throughout the 
therapy.  
CVVH-Heparin 
 CRRT with systemic heparin anticoagulation was delivered in pre- post-dilution continuous-veno-
venous-hemofiltration (CVVH) mode with standard substitution solution (Multibic®). Initial dose was 
set at 25ml/kg/h with approximately 33% of the dose delivered as pre-dilution. Heparin was 
administered as a continuous infusion via a separate central or peripheral venous line. Heparin 
infusion was titrated to aim for an anti-Xa activity between 0.3 and 0.6 IU/ml. 
In patients with contra-indications to both RCA and heparin, a similar protocol was followed but with 
a lower anti-Xa activity target or no anticoagulation at all according to clinician’s judgement.  
Data Collection 
Patients' characteristics and outcomes 
All data were manually collected using electronic chart records (Metavision®, IMD Soft, Tel Aviv, 
Israel) and Soarian® (Cerner, North Kansas City, USA). We collected patients' characteristics on 
admission as well as ICU and hospital outcomes (survival, length of stay and dialysis dependence). 
For the purpose of the study, dialysis dependence was defined as the receipt of any form or renal 
replacement therapy (RRT) within 72hrs of discharge. For patients with multiple ICU stays, only the 
first was considered for baseline data and the last for outcome data. 
CRRT Sessions 
For all included patients, we then reviewed all consecutive CRRT sessions. A CRRT session was 
defined as the period of time during which a single CRRT set was connected to a patient. Temporary 
disconnections were considered as part of a session (recirculation mode). For each session, we have 
recorded: therapy modality (CVVH or CVVHD), anticoagulation method, delivered dose, filter lifespan 
and reason for interruption and complications.  
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Complications  
Electronic medical records were screened for biological alterations occurring during each CRRT 
session. To assess for complications, we recorded the lowest and highest values of pre-determined 
parameters during a session and the following 12 hours. The following pre-defined complications 
were recorded: thrombocytopenia (thrombocyte level <150 G/L), hypothermia (body temperature 
<35°C), metabolic acidosis (pH < 7.35 and/or BE < -2), metabolic alkalosis (pH > 7.45 and/or BE > 2), 
hypocalcemia (serum calcium <1.05 mmol/L), hypernatremia (serum sodium >145 mmol/L) and 
significant hemorrhage (recorded in medical notes and/or >2 red packed cells transfused during 
sessions). Classifications of alterations are detailed in table 1 of the Appendix. Alterations present on 
therapy initiation (pre-existing anomaly) or with an obvious alternate explanation were not 
considered. For CRRT sessions ran in CVVHD-RCA mode, we also collected changes in blood or 
dialysate pump flow rate as well as total over ionized calcium ratio and need for calcium substitution 
to assess citrate intoxication. For this part of the study, only filters with a lifespan longer than six 
hours were considered. 
Delivered dose 
Delivered dose was estimated as the total of dialysate or pre and post-dilution flow rates. For this part 
of the study, only filters with a lifespan longer than six hours were considered. 
Statistical Analysis 
Continuous data with normal distribution are reported as mean (standard deviation) and compared 
using Student t-test. Non-normally distributed data are reported as median (interquartile range) and 
compared using Mann–Whitney U test. Ordinal data are reported as number (percentage) and 
compared by means of Fisher’s exact or Chi-square test as appropriate. Kaplan-Meier survival 
analyses with log-rank test were used to compare circuits' lifespan. A two-sided P value < 0.05 was 
considered significant. Prism 8.0.1 and SPSS version 25 were used for statistical analyses. 
Results 
Patients' demographics 
During the study period (Fig. 1), 1806 patients (2011 admissions) were admitted to our ICU. Of those, 
137 (7.6%) required RRT including 16 who denied institutional consent to participate in research. 
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Hence, 121 patients (126 stays) were included in this study and analyzed. Their characteristics on 
ICU admission are presented in table 1. Briefly, 81(66.9%) were males, their median age was 69 years 
(IQR 11) and median weight 79.9 kg (IQR 25). Median Charlson score was 6.0 (IQR 4.0) and 48 
(39.7%) had some degree of pre-existing chronic kidney disease, including 18 (15.1 %) who required 
chronic hemodialysis. The main reason for ICU admission was sepsis (24.6%) followed by cardiogenic 
shock (15.9%) and hemorrhagic shock (8.7%).  
Outcomes 
Among the 121 patients included in the study, 48 (39.7%) died while in ICU and 10 (8.3%) while on 
the ward (overall in-hospital mortality 47.9%). Median ICU length of stay was 8.9 (IQR 15.1) days, 
median hospital length of stay was 23.7 (IQR 41.2) days. Among survivors, 44 (59.5%) required RRT 
on ICU discharge (including 16 with pre-existing ESRD) and 26 (41.3%) required RRT on hospital 
discharge (including 13 with pre-existing ESRD). 
CRRT sessions 
Altogether, 691 CRRT sessions were administered to eligible patients for a total duration of 26'055 
hours (1'085.6 days). Of those, 400 (57.9%) were performed in CVVHD-RCA mode and 291 (42.2%) 
in CVVH-Heparin mode. Among all considered ICU admissions, both modalities were sequentially 
administered in 44 (34.9%) admissions. A single modality was used throughout other admissions, 
CVVHD-RCA in 51 (40.5%) and CVVH-Heparin in 31 (24.6%).  
Filter lifespan 
As presented in figure 2, CVVHD-Citrate mode was associated with a longer filter life compared with 
CVVH-Heparin (median duration 54.9 hours (IQR 44.6) vs 15.3 hours (IQR 22.4), p<0.0001). This 
difference remained even when CVVH-Heparin sessions during with less than 625 UI/h of heparin 
was administered, were excluded (p<0.0001), Fig.1 of the Appendix. As shown in table 2, in CVVHD-
RCA mode, only 28 (8.8%) of the sessions were interrupted as a result of filter clotting versus 113 
(42.8%) in CVVH-heparin mode (p<0.0001). As a consequence, median delivered dose was much 
higher during sessions in CVVHD-RCA mode: 1.5 (IQR, 1.2) L/kg compared to 0.5 (IQR, 0.7) L/kg in 
sessions in CVVH-Heparin mode (p<0.0001).  
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Complications 
Complications occurring during CRRT were assessed in 636 CRRT sessions with a duration >6hrs 
(385 CVVHD-RCA, 251 CVVH-Heparin). Main results are presented in Figure 3 and 4.  
Electrolytes 
Hypocalcemia occurred more frequently during CVVHD-RCA sessions compared with CVVH-Heparin 
sessions: 96 (25.07%) vs 26 events (10.79%), p<0.0001. However, this difference disappeared when 
only moderate and severe hypocalcemia (<0.95 mmol/L) were considered (5 (1.3%) vs 3 (1.2%) 
p=0.99). There was no difference in the rate of observed hypernatremia between the two modalities 
13 (3.4%) vs 4 (2.0%) (p=0.44). 
Acid-base balance 
Overall, metabolic acidosis occurred more frequently during CVVHD-RCA sessions compared with 
CVVH-Heparin sessions (77 (20.2%) vs 18 (7.2%) (p<0.0001). When only severe (pH<7.20 and/or 
BE<-6) acidosis was considered, no statistically significant difference was observed between the two 
groups (16 (4.2%) vs 6 (2.4%) (p=0.27).  
Similarly, metabolic alkalosis, was more frequently observed during CVVHD-RCA sessions than 
during CVVH-Heparin sessions:  187 (48.8%) vs 43 (17.1%), (p=0.0001). This different persisted even 
when only severe (pH>7.60 and/or BE>6) alteration were considered (54 (14.1%) vs 0 
(0%)(p<0.0001).  
Therapy adaptations 
Blood pump flow was adapted at least once in 53 (13.8%) CVVHD-RCA circuits and dialysate flow in  
38 (9.9%). 
Citrate intoxication 
One patient with severe circulatory shock was diagnosed with citrate intoxication although he did not 
fulfill all criteria (peak total / ionized calcium ratio 2.40). For this patient, therapy was replaced with 
CVVH-Heparin and the clinical situation eventually improved.  
Another patient had a transient elevated total/ionized calcium ratio (peak 2.53) with no other sign of 
intoxication. Therapy was maintained with parameters normalization over 48 hours. This situation 
was therefore not considered as citrate intoxication.  
10 
 
Hematological complications 
The incidence of thrombocytopenia was similar during CVVHD-RCA and CVVH-Heparin sessions (6.6 
vs 11.1% (p<0.07). However, when only severe (<100G/l) alterations were considered, there was less 
thrombocytopenia in therapies ran in CVVHD-RCA group 3 (0.8%) compared to CVVH-Heparin mode 
15 (6.4%), p<0.0001.  
Clinically significant hemorrhage were observed at a similar rate during CVVHD-RCA and CVVH-
Heparin sessions (23 (5.6%) vs 11 (4.4%) (p=0.47). Similarly, there was no difference in terms of 
number of sessions during which >2 PRBC were transfused (35 (9.1%) vs 22 (8.8%), p=0.99). 
Heparin induced thrombocytopenia (HIT) was diagnosed in one patient while undergoing CVVH-
Heparin CRRT.  
Other complications 
The rate of documented hypothermia (body temperature <35°) was similar during CVVHD-Citrate 
and CVVH-Heparin sessions (29 (7.5%), 22 (8.8%), p=0.55). 
Discussion 
Summary of key findings 
We performed a retrospective observational study on 691 consecutive CRRT sessions to assess the 
rate and the severity of complications associated with RCA outside the protected setting of 
randomized controlled trials. We found that, compared with heparin anticoagulation, RCA was 
associated with an almost fourfold filter lifespan. Such difference was linked to a much lower rate of 
clotting issues within the circuit. We found that RCA was associated with a higher incidence of 
electrolyte disorders, in particular acid-base alterations. However, the vast majority of these 
abnormalities were minor and of unknown significance. In our selected patients group, only one 
possible citrate intoxication was observed and no major complication was observed.  
Comparison with previous studies 
The observed longer filter life and lower rate of circuit clotting associated with RCA is largely 
consistent with previously reported data (5,11–15). In particular, it is similar to that observed in 
cohorts using a similar protocol (10). Although we did not perform a cost analysis, our data confirm 
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that RCA introduction should logically translate in important costs savings. In addition, longer filter 
life translates into lower workload for the nursing staff and improved therapy quality (19).  
The reported incidence of metabolic complications associated with RCA is higher than previously 
reported (11,13,14). This is possibly related to the way our data was collected: indeed, we have 
elected to report every single, even transient and perhaps insignificant event. However, when only 
severe alterations were considered, only metabolic alkalosis was more commonly observed during 
RCA. Their clinical relevance cannot be assessed with our study design since patients' allocation was 
not random. However, it might also be related to our team's limited experience at the time of the 
study. Indeed, timely therapy adaptation (changes in blood flow or dialysate rate) might have 
prevented the occurrence of some moderate or severe acid-base alterations. However, such 
adaptation were rarely performed. Similarly, the observed hypocalcemia could probably have been 
avoided by more experience teams.  
Several cohorts have reported a lower rate of hemorrhagic complication and (3,4,16–18). We have 
not observed such difference. This is probably related to the very low rate of hemorrhagic 
complications in our population. For similar reasons, we have not observed a difference in the rate in 
HIT (only one case).    
Study implications  
Our data confirm that, even in a center with intermediate experience with RCA, very long circuit 
lifespan can be achieved. However, the observed higher rate of complications, and the fact that the 
majority of these complications could have been prevented with minor therapy adjustments 
emphasize the importance of education and experience when RCA is applied. Implementation of a 
RCA in a unit should be associated with a strict protocol and intensive education to minimize therapy 
associated complications.  
Strengths and limitations 
This study has several strength. First, our data is based on a large number of observations, close to 
700 circuits have been evaluated. Detailed chart review was performed by a single investigator 
enabling the report of granular data on CRRT practice. Second, we believe that our center is ideal for 
evaluating RCA complications in real life since it is large (2000 admissions per year) with a large CRRT 
practice (>100 patients treated per year) but a relatively limited experience with RCA (at the time of 
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the study) and a large number of nursing staff with an important turn-over. Hence, our findings might 
apply to many similar sized units and perhaps even to smaller ICUs although this remains to be 
demonstrated.   
However, this study also has several limitations worth discussing. First, as a monocentric 
observational study, result might be associated with bias. There might be limitations in the quality of 
the data related to nursing/medical documentation. However, complications that were a priori 
defined would all be identified by routine nursing surveillance in a patient undergoing CRRT. In 
particular, temperature, arterial blood gas analyses and electrolyte levels measurement are all part 
of routine follow-up for such patients in our unit. In addition, our protocol mandate regular 
monitoring of systemic and total ionized calcium. All data are automatically entered in our electronic 
chart records system minimizing the risk of data loss. 
Second, the allocation of anticoagulation regimen was far from random since, as per study protocol, 
RCA was considered to be contra-indicated in patients with liver failure (defined as a PT<40%) or 
circulatory shock (defined as a serum lactate >4 mmol/l or need for noradrenaline at a rate >25 
µg/min). In addition, both modalities were used in more than a third of the patients. Therefore, no 
inference on outcomes and mortality in particular can be made in this study. However, this bias is 
likely to bias result in favor of CVVHD-RCA circuits. Therefore, the higher rate of complication might 
be under-evaluated. 
Third, we have not accounted for the fact that a given complication might have occurred several times 
in a given patient in different CRRT sessions. This issue might artificially increase the rate of 
complications. In addition, we can only report on complications' severity and not their duration. Here 
again, the method chosen should not bias comparison between two groups. However, both these 
limitations should not bias group comparisons as it applies to both in a similar way.  
Conclusions 
In a center with intermediate experience, consistent with randomized controlled studies, regional 
citrate anticoagulation for CRRT, was associated with a much longer circuit lifespan compared with 
systemic heparin. However, it was associated with a higher rate of mild metabolic complications in 
particular metabolic alkalosis. Some of these complications could have been prevented by therapy 
adaptation. Medical and nursing staff education is of major importance in the implementation of a 
RCA protocol.   
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Figures and Tables  
 
Patients (n=121)  
Demographics  
Median age - (IQR) - years 69 (11) 
Median body weight - (IQR) - kg 79.9 (25) 
Male sex - no. (%) 81 (66.9) 
Illness severty  
Median Charlson score - (IQR) 6 (4) 
Renal function parameters  
Mean baseline creatinine - (SD) - umol/L 93.5 (64.8) 
Mean GFR MDRD - (SD) -  ml/min/1.72m2 67.9 (48.3) 
Co-existing conditions  
Chronic kidney injury - no. (%) 48 (39.7) 
Hemodialysis dependancy - no. (%) 18 (15.1) 
Diabetes mellitus - no. (%) 39 (32.2) 
Chronic hypertension - no. (%) 74 (61.2) 
Congestive heart failure stage I (FEVG=40-50%) - no. (%) 10 (8.3) 
Congestive heart failure stage II (FEVG < 40%) - no. (%) 20 (16.5) 
Peripheral arterial disease - no. (%) 25 (20.7) 
ICU admissions (n=126)  
Diagnostic at ICU admission  
Septic shock - no. (%) 31 (24.6) 
Cardiogenic shock - no. (%) 20 (15.9) 
Hemorrhagic shock - no. (%) 11 (8.7) 
Cardiac arrest - no. (%) 10 (7.9) 
Acute kidney failure - no. (%) 7 (5.6) 
Acute respiratory failure - no. (%) 6 (4.8) 
Intoxication - no. (%) 2 (1.6) 
Others - no. (%) 39 (31) 
Type of admission (2 missing)                                                                                              
Medical - no. (%) 53 (44) 
Surgical - no. (%) 61 (50.4) 
Others - no. (%) 10 (8.3) 
CRRT modality   
CVVH-Heparin - no. (%) 31 (24.6) 
CVVHD-RCA - no. (%) 51 (40.5) 
CVVH-Heparin and CVVHD-RCA - no.(%) 44 (34.9) 
 
Table 1: Patients' demographics (n=121) and ICU stays characteristics (n=126). 
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Circuits (n=690) CVVHD-RCA CVVH-Heparin P values 
Renal replacement therapy characteristics    
Total number - no. (%) 400 (57.9) 291(42.2) - 
Median filter lifespan - (IQR) - hours 54.9 (44.6) 15.3 (22.4) <0.0001 
Median dose delivered - (IQR) - ml/kg 1.5 (1.2) 0.5 (0.7) <0.0001 
Median time between ICU admission and Therapy initiation - (IQR) - hours 45 (77.8) 38.8 (59.8) <0.0002 
Reason for therapy interruption  (114 missing)    
Reason for therapy interruption indicated - no. (%)  317 (79.25) 260 (89.34) <0.0001 
Filter clotting - no. (%)  28 (8.8) 113 (43.5) <0.0001 
End of therapy - no. (%)  137 (43.2) 64(24.6) <0.0001 
Time limit of 72h reached - no. (%)  134 (42.3) 22(8.5) <0.0001 
Elevation of transmembrane pressure - no. (%)  18 (5.7) 61(23.5) <0.0001 
Missing Data – no. (%) 83 (20.8) 31(11.742)  -  
 
 
Table 2: CRRT Circuit parameters and reasons for interruption comparison between CVVHD-RCA 
and CVVH-Heparin. 690 circuits 
RCA: regional citrate anticoagulation 
CVVHD: Continuous veno-venous hemodialysis 
CVVH: continuous veno-venous hemofiltration 
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Figure 1: Patients and circuits flow chart. 
All CRRT circuits were analyzed for lifespan and reason of interruption, however only CRRT sessions 
lasting more than 6 hours were analyzed for complications and dose delivered. 
CVVHD-citrate =Continuous Veno-Venous HemoDialysis with regional citrate anticoagulation; CVVH-
Heparin = Continuous Veno-venous Hemofiltration with systemic heparin anticoagulation. 
 
 
  
137 patients (143 stays) 
received CRRT between
Jan. and Dec 2016
121 patients (126 stays) 
included in the study
16 patients (17 stays ) 
declined consent
400 circuits in 
CVVHD-Citrate 
mode 
55 circuits with
<6 hours lifespan
385 (60.5%) circuits in 
CVVHD – Citrate mode
251 (39.5%) circuits in 
CVVH – Heparin Mode
691 CRRT circuits
Analyzed for lifespan and 
reason of interruption
291 circuits in 
CVVH-Heparin
mode
Analyzed for delivered
dose and complications
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Figure 2: Kaplan-Meier plot for circuit lifespan in CVVHD-Citrate versus CVVH-Heparin methods. 
Median lifespan was 54.9 hours (IQR 44.6) for CVVHD-RCA vs. 15.3 hours (IQR 22.4) for CVVH-
Heparin. P value for log-rank test.  
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Figure 3: Therapy associated acid-base alterations  
Complications recorded for CRRT session with a lifespan > 6 hours (385 CVVHD-RCA sessions and 
251 CVVH-Heparin sessions). Panel A: Metabolic acidosis: pH<7.35 &/or BE=-2:-4 (benign), pH<7.25 
&/or BE=-4:-6 (moderate), or  pH<7.20 &/or BE<-6 (severe) 
Panel B: Metabolic alkalosis pH>7.5 &/or BE=2:4 (benign), pH>7.55 &/or BE=4:6 (moderate), pH>7.6 
&/or BE>6 (severe) 
* p<0.05 for overall comparison; ** p<0.01 for overall comparison; ∇ p<0.05 for comparison between 
severe events; ∇∇ p<0.01 for comparison between severe events. 
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Figure 4: Other therapy associated complications  
Complications recorded for CRRT session with a lifespan > 6 hours (385 CVVHD-RCA sessions and 
251 CVVH-Heparin sessions). 
Definitions:  
A. Thrombopenia: thrombocyte level <150G/L (benign), <100 G/L (moderate) or <50 G/L (severe);  
B. Hypothermia:  body temperature 32-35°C (benign), 32-28°C (moderate) 
E. Hypernatremia: Sodium plasma level >145mmol/L (benign), >152mmol/L (moderate) 
F. Hypocalcemia: systemic ionized calcium <1.05mmol/L (benign), <0.95mmol/L (moderate) or 
<0.85mmol/L (severe). 
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* p<0.05 for overall comparison; ** p<0.01 for overall comparison; ∇ p<0.05 for comparison between 
severe events; ∇∇ p<0.01 for comparison between severe events. 
 
 
